Definitely been plenty of hyperbole on this thread lately. I've lost count of the number of people saying you don't want to miss the next announcement.
It makes me wonder if any of those saying this have researched any other diagnostic companies making similar announcements and where their market caps are at? I have and have found 3.
The most closely aligned of these to PEB and the one with the highest market cap is MDxHealth, a Belgium company. It's flagship product is called ConfirmMDx prostate cancer diagnosis, although they also have others in the pipeline including colon, lung and a test for brain tumors.
If you use this link you will see on 1 October 2013
http://www.reuters.com/article/2013/...pe=companyNews they also coincidentally signed up FEDMED and ACPN (same announcement), but on top of that they have also made other deals, including with other US insurers meaning their product currently has total coverage of 130M compared to PEB which presently has 50M.
They also had Q1, yes quarter, not annual sales of 1.1M euro up 51%.
So what market cap has been assigned to MDxHealth by their local exchange? Market Cap 98M or approx 160M NZD. PEB's market cap is currently almost 200M more at yesterdays close at 350M, with currently less coverage and I expect less sales. It was only very recently that PEB had a market cap of 486M, 300M+ more than MDx, when it was priced at $1.75.
I do recall some time somebody on here saying NZ seems to put a premium on its BIO's compared to Australia due to lack of choice. Maybe compared to Belgium as well?
Yes do get excited by the announcements, but like Blobbles has been saying, do also try to keep at least one foot on the ground when the hype abounds and surrounds.
DYOR
Discl: Like the company, sidelined as the hype settles down